Similar correlations between therapeutic efficacy and the tumor specific IFN-γ production were found for effector T cells derived from lymph nodes (LN) draining the vaccine sites of MCA-205 sarcoma or B16BL6 melanoma tumor cell lines [10-13]. The gene discussed is IFNG; the disease is sarcoma.